Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180329001

Enrollment

Registered

2018-03-29

Start date

2018-04-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal women who diagnosed as pelvic organ prolapse and chosing vaginal pessary for treatment option pelvic organ prolapse&#44

Interventions

Gynoflor (Estriol 0.03 mg plus Lactobacillus acidophilus 100 million viable cells vaginal tablet),No intervention

Experimental Drug,No Intervention No treatment

Gynoflor,No intervention

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Postmenopausal women Symptomatic pelvic organ prolapse Choose vaginal pessary as choice of treatment Not using exogenous estrogen

Exclusion criteria

Exclusion criteria: Hypersensitivity to the anti-infective agent or test preparation Vaginal bleeding of unknown origin Estrogen-dependent neoplastic disease Breast cancer Immunosuppression and clinically manifest sexually transmitted diseases History of bacterial vaginosis, trichomoniasis or vulvovaginal candidiasis before enrollment

Design outcomes

Primary

Measure	Time frame
The incidence of bacterial vaginosis 3 months Amselâ€™s criteria	—

Secondary

Measure	Time frame
The pessary-related complications 3 months Normal flora index and Questionnaire (ICIQ-VS) and Visual analog scale	—

Countries

Thailand

Contacts

Public ContactKeerati Chiengthong

Faculty of medicine,King chulalongkorn memorial hospital

keerati_c@outlook.co.th0815840571

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026